The primary endpoint was change in HbA@c after @ weeks of treatment , and the main objective was to assess the non-inferiority of IDegLira to insulin degludec ( with an upper @ % CI margin of @ % ) , and the superiority of IDegLira to liraglutide ( with a lower @ % CI margin of @ % ) .